Core Viewpoint - BiomX Inc. has issued a statement addressing unusual market activity in its common stock, indicating no material developments have occurred that have not been previously disclosed [1][2]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating specific pathogenic bacteria [3]. - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to create customized phage compositions against proprietary bacterial targets [3].

Core Insights - BiomX Inc. will report its third quarter 2025 financial results and program updates on November 12, 2025, before the U.S. financial markets open [1] - A conference call and live audio webcast will be held at 8:30 a.m. ET on the same day to discuss the financial results and program updates [1][2] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria for chronic diseases with significant unmet needs [4] - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against proprietary bacterial targets [4]